The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients

BMC Gastroenterology

Volumn 10, Issue , 2010, Pages

  Bastida, Guillermo ^a,b   Nos, Pilar ^a,b   Aguas, Mariam ^a   Beltrán, Belén ^a,b   Iborra, Marisa ^a   Ortiz, Vicente ^a,b   Garrigues, Vicente ^a,b   Estevan, Rafael ^a   Ponce, Julio ^a,b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; IMMUNOSUPPRESSIVE AGENT; METHYLTRANSFERASE; MONOCLONAL ANTIBODY; THIOPURINE METHYLTRANSFERASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; DRUG WITHDRAWAL; ENTERITIS; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SHORT FORM 36; SPAIN; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; BLOOD; DRUG ADMINISTRATION; ENZYMOLOGY; FOLLOW UP; IMMUNOMODULATION; MIDDLE AGED; REMISSION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; METHYLTRANSFERASES; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; REMISSION INDUCTION; YOUNG ADULT;

EID: 77951156441     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-10-26     Document Type: Article

References (48)

1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007, 369:1627-40. 10.1016/S0140-6736(07)60750-8, 17499605.
2. Love JR, Irvine EJ, Fedorak RN. Quality of life in IBD. J Clinical Gastroenterology 1992, 14:15-19.
3. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, Kinnear D, Saibil F, McDonald JW. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994, 106:287-96.
4. Casellas F, Arenas JI, Baudet JS, Fábregas S, García N, Gelabert J, Medina C, Ochotorena I, Papo M, Rodrigo L, Malagelada JR. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005, 11:488-96. 10.1097/01.MIB.0000159661.55028.56, 15867589.
5. Rubin GP, Hungin AP, Chinn DJ, Dwarakanath D. Quality of life in patients with established inflammatory bowel disease: a UK general practice survey. Aliment Pharmacol Ther 2004, 19:529-35. 10.1111/j.1365-2036.2004.1873.x, 14987321.
6. Casellas F, López-Vivancos J, Badia X, Vilaseca J, Malagelada JR. Influence of inflammatory bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol 2001, 13:567-72. 10.1097/00042737-200105000-00017, 11396538.
7. Canavan C, Abrams KR, Hawthorne B, Drossman D, Mayberry JF. Long-term prognosis in Crohn's disease: factors that affect quality of life. Aliment Pharmacol Ther 2006, 23:377-85. 10.1111/j.1365-2036.2006.02753.x, 16422997.
8. Hjortswang H, Järnerot G, Curman B, Sandberg-Gertzén H, Tysk C, Blomberg B, Almer S, Ström M. The influence of demographic and disease-related factors on health-related quality of life in patients with ulcerative colitis. Eur J Gastroenterol Hepatol 2003, 15:1011-20. 10.1097/00042737-200309000-00012, 12923375.
9. Hjortswang H, Almer S, Ström M. The network: a strategy to describe the relationship between quality of life and disease activity. The case of inflammatory bowel disease. Eur J Gastroenterol Hepatol 1999, 11:1099-104. 10.1097/00042737-199910000-00005, 10524638.
10. Irvine EJ. Quality of life issues in patients with inflammatory bowel disease. Am J Gastroenterol 1997, 92:18S-24S.
11. Timmer A, McDonald JWD, MacDonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2007, (1):CD000478. DOI: 10.1002/14651858.CD000478.pub2.
12. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006, 55:47-53. 10.1136/gut.2005.068809, 1856376, 15972298.
13. Prefontaine E, MacDonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2009, (4). Art. No.: CD000545. DOI: 10.1002/14651858.CD000545.pub2.
14. Prefontaine E, Sutherland LR, MacDonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2009, (1). Art. No.: CD000067. DOI: 10.1002/14651858.CD000067.pub2..
15. Han SW, McColl E, Barton JR, James P, Steen IN, Welfare MR. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm Bowel Dis 2005, 11:24-34. 10.1097/00054725-200501000-00004, 15674110.
16. Casellas F, López-Vivancos J, Casado A, Malagelada JR. Factors affecting health related quality of life of patients with inflammatory bowel disease. Qual Life Res 2002, 11:775-81. 10.1023/A:1020841601110, 12482161.
17. Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E. International Budesonide-Mesalazine Study Group. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life. Am J Gastroenterol 2002, 97:649-653. 10.1111/j.1572-0241.2002.05544.x, 11922560.
18. Irvine EJ, Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Nilsson LG, Persson T. Quality of life rapidly improves with budesonide therapy for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. Inflamm Bowel Dis 2000, 6:181-7.
19. Cohen RD, Brodsky AL, Hanauer SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporine. Inflamm Bowel Dis 1999, 5:1-10.
20. Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003, 98:2232-2238. 10.1111/j.1572-0241.2003.07674.x, 14572573.
21. Lichtenstein GR, Bala M, Han C, DeWoody K, Schaible T. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002, 8:237-243. 10.1097/00054725-200207000-00001, 12131606.
22. van Balkom BP, Schoon EJ, Stockbrügger RW, Wolters FL, van Hogezand RA, van Deventer SJ, Oldenburg B, van Dullemen HM, Russel MG. Effects of anti-tumour necrosis factor-alpha therapy on the quality of life in Crohn's disease. Aliment Pharmacol Ther 2002, 16:1101-1107. 10.1046/j.1365-2036.2002.01268.x, 12030951.
23. Feagan BG, Sandborn WJ, Hass S, Niecko T, White J. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. Am J Gastroenterol 2007, 102:2737-46. 10.1111/j.1572-0241.2007.01508.x, 18042106.
24. Delaney CP, Kiran RP, Senagore AJ, O'Brien-Ermlich B, Church J, Hull TL, Remzi FH, Fazio VW. Quality of life improves within 30 days of surgery for Crohn's disease. J Am Coll Surg 2003, 196:714-721. 10.1016/S1072-7515(03)00131-5, 12742203.
25. Casellas F, Lopez-Vivancos J, Badia X, et al. Impact of surgery for Crohn's disease on health-related quality of life. Am J Gastroenterol 2000, 95:177-182. 10.1111/j.1572-0241.2000.01681.x, 10638579.
26. Oxelmark L, Hillerås P, Dignass A, Mössner J, Schreiber S, Kruis W, Löfberg R. Quality of life in patients with active ulcerative colitis treated with selective leukocyte apheresis. Scand J Gastroenterol 2007, 42:406-7. 10.1080/00365520600881060, 17354122.
27. Bernklev T, Jahnsen J, Schulz T, Sauar J, Lygren I, Henriksen M, Stray N, Kjellevold T, Aadland E, Vatn M, Moum B. Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis. Eur J Gastroenterol Hepatol 2005, 17:1037-1045. 10.1097/00042737-200510000-00006, 16148548.
28. Blondel-Kucharski F, Chircop C, Marquis P, Cortot A, Baron F, Gendre JP, Colombel JF. Groupe d'Etudes Thérapeutique des Affections Inflammatoires Digestives (GETAID). Health-related quality of life in Crohn's disease: a prospective longitudinal study in 231 patients. Am J Gastroenterol 2001, 96:2915-2920. 10.1111/j.1572-0241.2001.04681.x, 11693326.
29. Calvet X, Gallardo O, Coronas R, Casellas F, Montserrat A, Torrejón A, Vergara M, Campo R, Brullet E. Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease. Inflamm Bowel Dis 2006, 12:692-6. 10.1097/00054725-200608000-00004, 16917223.
30. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989, 170:2-6. 10.3109/00365528909091339, 2617184.
31. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(suppl A):5-36.
32. Bastida Paz G, Nos Mateu P, Aguas Peris M, Beltrán Niclós B, Rodríguez Soler M, Ponce García J. Optimization of immunomodulatory treatment with azathioprine or 6-mercaptopurine in inflammatory bowel disease. Gastroenterol Hepatol 2007, 30:511-6. 10.1157/13111681, 17980127.
33. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-83. 10.1097/00005650-199206000-00002, 1593914.
34. Alonso J, Prieto L, Antó JM. The Spanish version of the SF-36 Health Survey (the SF-36 health questionnaire): an instrument for measuring clinical results. Med Clin (Barc) 1995, 104:771-776.
35. López-Vivancos J, Casellas F, Badia X, Vilaseca J, Malagelada JR. Validation of the Spanish versión of the inflammatory bowel disease Questionnaire on Ulcerative Colitis and Crohn's Disease. Digestion 1999, 60:274-280. 10.1159/000007670, 10343142.
36. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J, Sutherland LR. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132:763-86. 10.1053/j.gastro.2006.12.038, 17258735.
37. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Löfberg R, Modigliani R, Present DH, Rutgeerts P, Schölmerich J, Stange EF, Sutherland LR. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002, 122:512-30. 10.1053/gast.2002.31072, 11832465.
38. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989, 27:S178-89. 10.1097/00005650-198903001-00015, 2646488.
39. Fitzpatrick R, Davey C, Buxton MJ, Jones DR. Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess 1998, 2:1-74.
40. Ware JE, Snow KK, Kosisnki M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. 1993, Boston, MA: The Health Institute, New England Medical Centre.
41. Gregor JC, McDonal JW, Klar N, et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis 1997, 3:265-76.
42. Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther 2005, 22:1-16. 10.1111/j.1365-2036.2005.02520.x, 15963074.
43. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004, 99:91-96. 10.1046/j.1572-0241.2003.04010.x, 14687148.
44. Reinisch W, Sandborn WJ, Bala M, Yan S, Feagan BG, Rutgeerts P, Radford-Smith G, Xu S, Eisenberg D, Olson A, Colombel JF. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis 2007, 13:1135-40. 10.1002/ibd.20165, 17476675.
45. Blondel-Kucharski F, Chircop C, Marquis P, Cortot A, Baron F, Gendre JP, Colombel JF. Groupe d'Etudes Thérapeutique des Affections Inflammatoires Digestives (GETAID). Health-related quality of life in Crohn's disease: a prospective longitudinal study in 231 patients. Am J Gastroenterol 2001, 96:2915-2920. 10.1111/j.1572-0241.2001.04681.x, 11693326.
46. Norman GR, Sridhar FG, Guyatt GH, Walter SD. Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Med Care 2001, 39:1039-47. 10.1097/00005650-200110000-00002, 11567167.
47. Han SW, McColl E, Barton JR, James P, Steen IN, Welfare MR. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm Bowel Dis 2005, 11:24-34. 10.1097/00054725-200501000-00004, 15674110.
48. Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, Bala M, Johanns J, Olson A, Hanauer SB. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007, 102:794-802. 10.1111/j.1572-0241.2007.01094.x, 17324131.